Response to osimertinib by RECIST 1.1 in real-world practice.

NIAID Data Ecosystem2026-03-10 收录

真实世界肿瘤疗效研究

靶向药物疗效评估

数据链接：

https://figshare.com/articles/dataset/Response_to_osimertinib_by_RECIST_1_1_in_real-world_practice_/7567754 数据链接链接失效反馈

官方服务：

资源简介：

Response to osimertinib by RECIST 1.1 in real-world practice.

创建时间：

2019-01-09

Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery

结肠癌辅助治疗

靶向药物疗效评估

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin, or fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from

NIAID Data Ecosystem70

Efficacy and Safety of Oral Erlotinib in TRPV3-related Olmsted Syndrome: a Case Series

罕见皮肤病

靶向药物疗效评估

Supplementary figures (A-B, C-D). Clinical images of OS patients treated with erlotinib A and B, patient 10, with the TRPV3 p.Gly573Ser mutation, achieved complete remission of hyperkeratosis. C and

NIAID Data Ecosystem40

Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer

转移性结直肠癌治疗

靶向药物疗效评估

The purpose of this study is to evaluate, in terms of overall survival, the benefit of monoclonal antibodies in the start time of the diagnosis of advanced disease or administer a deferred basis after

NIAID Data Ecosystem30

A 46-year old women with DFSP at paravertebral site at the level of L3–4 and RUL zone of chest.

隆突性皮肤纤维肉瘤影像评估

靶向药物疗效评估

Lumbar spine MRI and chest CT were taken. A, before initiation of treatment with imatinib. B, after 4 months treatment with imatinib. C, after further 2 months treatment with imatinib and 3 months tre

NIAID Data Ecosystem50

DataSheet_1_Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report.docx

罕见EGFR突变肺癌

靶向药物疗效评估

IntroductionPreviously, we developed a database of 693 patients with NSCLC and uncommon EGFR mutations treated with afatinib. Here, we provide an update of >1000 patients, with more data on specific m

NIAID Data Ecosystem30

Response to osimertinib by RECIST 1.1 in real-world practice.

资源简介：

相关数据集